Magnetic Nanoparticles and Gadolinium Agents for MRI Imaging and Cancer Therapy
This community develops magnetic iron oxide nanoparticles and gadolinium-based compounds primarily to improve magnetic resonance imaging (MRI) contrast and to deliver targeted therapies for cancer and neurological diseases.
The work centers on synthesizing superparamagnetic iron oxide nanoparticles and gadolinium chelates to enhance MRI signal quality. These materials are engineered for use as contrast agents in diagnosing conditions such as multiple sclerosis, hepatocellular carcinoma, and breast cancer. A significant portion of the research focuses on drug delivery systems that use these magnetic particles to transport therapeutic agents across the blood-brain barrier or to specific tumor sites. Methods include chemical synthesis of oxide nanoparticles, magnetic hyperthermia for cancer treatment, and the application of deep learning to analyze resulting imaging data. The papers frequently describe the design of targeted therapy platforms and the evaluation of these agents in clinical and preclinical settings.
The largest share of the community's output is found in gadolinium research, accounting for 28.4% of all gadolinium research tracked, with 6,481 papers here. Iron research follows with a 9.6% share, comprising 3,047 papers.
The community comprises 21,337 papers, published most frequently in the Journal of Magnetic Resonance Imaging, Radiology, and Investigative Radiology.
Recent work continues to focus on the clinical application of superparamagnetic iron oxide nanoparticles and the development of lipid-polymer hybrid nanoparticles for oncological use. Studies also address the isolation of extracellular vesicles for targeted therapy and the use of anti-BCMA CAR-T therapy in progressive multiple sclerosis.
Papers behind this description
- Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy — Discover Oncology, 2025 — doi:10.1007/s12672-025-02198-8
- Smart nanoparticles for cancer therapy — Signal Transduction and Targeted Therapy, 2023 — doi:10.1038/s41392-023-01642-x
- Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation — Molecular Cancer, 2023 — doi:10.1186/s12943-023-01865-0
- Nanomedicine in cancer therapy — Signal Transduction and Targeted Therapy, 2023 — doi:10.1038/s41392-023-01536-y
- Preparation and Identification of Magnetic Iron Nanoparticle based on a Natural Hydrogel and its Performance in Targeted Drug Delivery — International Journal of Innovative Science and Research Technology (IJISRT), 2024 — doi:10.38124/ijisrt/ijisrt24may1088
- Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review — Life Sciences, 2024 — doi:10.1016/j.lfs.2024.122899
- Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery — Molecular Cancer, 2025 — doi:10.1186/s12943-025-02357-z
- NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial — The Lancet, 2023 — doi:10.1016/s0140-6736(23)01366-101366-1)
- Nanomedicine: How nanomaterials are transforming drug delivery, bio-imaging, and diagnosis — Next Nanotechnology, 2025 — doi:10.1016/j.nxnano.2024.100129
- Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems — Pharmaceutics, 2025 — doi:10.3390/pharmaceutics17020215
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention — Signal Transduction and Targeted Therapy, 2025 — doi:10.1038/s41392-025-02415-4
- Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis — Cell, 2025 — doi:10.1016/j.cell.2025.09.020
- Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review — Molecular Neurobiology, 2025 — doi:10.1007/s12035-025-05417-z
- Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics — Molecular Cancer, 2025 — doi:10.1186/s12943-025-02443-2
- Superparamagnetic iron oxide nanoparticles in clinical applications: current status and future perspectives — EBioMedicine, 2025 — doi:10.1016/j.ebiom.2025.106054
- Exosome engineering for targeted therapy of brain-infecting pathogens: molecular tools, delivery platforms, and translational advances — Frontiers in Medical Technology, 2025 — doi:10.3389/fmedt.2025.1655471